Videos

Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.

Leslie M. Randall, MD, associate professor of Gynecology/Oncology, University of California Irvine, discusses the use of olaparib as maintenance therapy in the treatment of patients with ovarian cancer.

James Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the use of endobronchial ultrasound (EBUS) in the diagnosis of lung cancer.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of in situ tumor vaccination across various types of cancer.

Adam Bass, MD, assistant professor of Medicine, Harvard Medical School, physician/scientist, Dana-Farber Cancer Institute, discusses the importance of individualizing treatments for patients with gastric/esophageal cancer.

Sundar Jagannath, MD, director, Multiple Myeloma Program, Tisch Cancer Institute at Mount Sinai Hospital, discusses the role of stem-cell transplant in the management of multiple myeloma.

Raffaele Califano, MD, consultant in medical oncology, The Christie Clinic, University Hospital of South Manchester, discusses the recent investigations into the use of immune checkpoint blockades in small cell lung cancer.

Madhav Dhodapkar, MBBS, clinical research program leader, Hematology Program, Yale Cancer Center, discusses the evolving field of immuno-oncology and the significant benefits it stands to have for patients.

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical application of the data on HER2 gene amplification in patients with metastatic colorectal cancer, as well as the benefits of using a therapy that combines trastuzumab and pertuzumab.

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.